Anti-CD19 mAb modified mesoporous titanium dioxide as exclusively targeting vector for efficient B-lymphoblastic leukemia therapy

B lymphoblastic leukemia (B-LL) is a clonal hematopoietic stem cell neoplasm derived from B-cell progenitors, which mainly occurs in children and adolescents one of the main causes death malignant tumors this population. The surface marker CD19 specifically expressed on membrane most B-cells, widely used as B-LL antigen-specific immunotherapy. In study, mesoporous titanium dioxide nanoparticles (MTNs)-based antibody drug delivery system was designed for treatment. Anti-CD19 monoclonal conjugated to PEGylated MTNs, doxorubicin (DOX) loaded nanoparticle. CD19-PEG-MTN/DOX nanoparticle could recognize CD19+ lines induced them apoptosis, but nontoxic normal cells. Further, after treated with nanoparticle, pro-apoptotic proteins Bax Caspase-3 KOPN 8 NALM-6 cells were significantly upregulated, anti-apoptotic Bcl2, MCL-1, HSP 70, BAG 3 downregulated, indicated activation apoptosis pathway by nanodrug. By contrast, didn't play part CD19−cell line U937. Besides, cytotoxicity low good biocompatibility. Collectively, promising antitumor nanodrug treatment B-LL.